Please login to the form below

fitusiran

This page shows the latest fitusiran news and features for those working in and with pharma, biotech and healthcare.

After delays to its phase 3 trials in haemophilia drug, fitusiran, due to blood clots last year, regulatory approval is not now expected until 2024.

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Meanwhile, another non-clotting factor drug for haemophilia – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.
Sanofi narrows focus, shedding diabetes and cardiovascular research

This includes a host of investigational therapies for rare disease and cancers, such as Fitusiran (an RNAi therapeutic for haemophilia A and B), BIVV001 (a factor VIII therapy for haemophilia A)
Roche’s Hemlibra scores broader NHS funding

Competition is heating up in haemophilia, however. Alnylam's late-stage candidate fitusiran is tipped as a major competitor to Hemlibra, while the first gene therapies are also on the horizon.
ACPs to lead gene therapies in haemophilia market growth

New therapies to hit existing players. Roche’s Hemlibra and Alnylam’s late-stage candidate fitusiran are likely to seize a bigger share of an expanded haemophilia market than gene therapies, ... The two drugs have distinct mechanisms – Hemlibra is
Sanofi exits R&D pact with Alnylam on rare disease

The R&D deal was tweaked in January last year, with Sanofi licensing an RNAi drug called fitusiran for haemophilia A and B as well as other rare bleeding disorders, but ... Prospects for haemophilia candidate fitusiran looked a little shaky in 2017 when

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

20 for 2020 – Five pharma leaders to watch in 2020

pipeline. The company submitted its lumasiran candidate for primary hyperoxaluria to the FDA and has another ATTR amyloidosis candidate – called vutrisiran – in late-stage along with Sanofi-partnered fitusiran for haemophilia
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

instead taking a lead marketing role for their co- developed haemophilia candidate fitusiran. ... Alnylam has three more RNAi medicines in its late stage pipeline: Fitusiran in haemophilia, being co-developed with Sanofi; inclisiran for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Associate Director - Global Healthcare Consulting: Highly competitive salary

Add my company

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Virtual Patient Engagement Program: A Customer Story: Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?: Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all: The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...

Email:
Password: